#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	5096	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2559	589.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1709	1709	C	739	C,T	620,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	5096	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2559	589.8	0	HET	.	.	.	C207T	.	207	207	C	732	732	C	658	C,T	421,124	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3895	641.3	0	.	n	.	0	T695C	SNP	695	695	T	1198	1198	C	622	C	518	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3895	641.3	0	.	n	.	0	A1638G	SNP	1638	1638	A	2141	2141	G	761	G,A	656,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3895	641.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2474	2474	C	754	C,T,A	652,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3895	641.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3100	3100	T	785	T,C,G	650,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3895	641.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2548	2548	A	763	A,G	663,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	798	folP	855	855	100.0	folP.l6.c17.ctg.1	2288	104.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1584	1586	AGC	186;186;187	A;G;C	162;165;161	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1814	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3669	147.6	1	SNP	p	S91F	1	.	.	271	273	TTC	668	670	TTC	137;136;137	T;T;C	118;120;123	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1814	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3669	147.6	1	SNP	p	D95G	1	.	.	283	285	GGC	680	682	GGC	136;136;136	G;G;C	115;122;117	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1814	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3669	147.6	1	SNP	p	G95N	0	.	.	283	285	GGC	680	682	GGC	136;136;136	G;G;C	115;122;117	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	664	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1876	106.2	1	SNP	p	G45D	0	.	.	133	135	GGC	747	749	GGC	172;171;170	G;G;C	141;140;143	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	470	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1304	107.5	0	.	n	.	0	A197.	DEL	197	197	A	757	757	A	182	A	160	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1802	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3369	160.0	1	SNP	p	D86N	0	.	.	256	258	GAC	732	734	GAC	232;232;233	G;A;C	193;186;194	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1802	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3369	160.0	1	SNP	p	R87W	0	.	.	259	261	CGT	735	737	CGT	232;232;232	C;G;T	198;196;194	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1802	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3369	160.0	1	SNP	p	S87R	1	.	.	259	261	CGT	735	737	CGT	232;232;232	C;G;T	198;196;194	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1802	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3369	160.0	1	SNP	p	R87I	0	.	.	259	261	CGT	735	737	CGT	232;232;232	C;G;T	198;196;194	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1802	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3369	160.0	1	SNP	p	S88P	0	.	.	262	264	TCC	738	740	TCC	232;229;229	T;C;C	194;197;194	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1404	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2919	143.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1702	1704	GGC	174;174;174	G,T;G,C;C	148,1;144,1;147	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	A311V	0	.	.	931	933	GCC	1406	1408	GCC	176;177;178	G,A,T;C;C,T,G	143,1,1;142;149,1,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	I312M	1	.	.	934	936	ATG	1409	1411	ATG	179;178;179	A;T;G,T	152;149;144,1	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	V316T	1	.	.	946	948	ACC	1421	1423	ACC	168;169;170	A;C;C	141;140;141	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	T316P	0	.	.	946	948	ACC	1421	1423	ACC	168;169;170	A;C;C	141;140;141	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1922	1924	ACC	176;177;177	A;C;C	150;151;151	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1976	1978	GCG	166;165;166	G;C;G	140;143;139	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1976	1978	GCG	166;165;166	G;C;G	140;143;139	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2099	2101	GGT	164;163;163	G;G;T,G	144;145;140,1	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2108	2110	AGC	159;159;159	A;G;C,A	136;141;139,1	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	1220	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2763	131.8	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2126	2128	CCG	150;150;150	C,G;C;G,A	134,1;133;123,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1636	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3534	138.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1832	1834	CCG	141;140;140	C,T;C;G	118,1;118;120	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	988	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2191	135.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	754	754	C	152	C	133	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	148	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1211	33.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	937	939	AAT	27;27;27	A;A;T	24;24;22	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	148	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1211	33.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	940	942	AAT	27;27;27	A;A;T	24;23;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	148	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1211	33.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	964	966	GCA	24;24;24	G;C;A	21;19;21	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	148	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1211	33.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	987	989	GTA	23;22;22	G;T;A	20;18;20	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	148	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1211	33.0	0	.	p	.	0	N237fs	FSHIFT	709	709	A	996	996	A	21	A	18	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	956	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	2078	137.2	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	744	746	CAG	210;210;209	C;A;G	177;177;177	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	956	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	2078	137.2	1	SNP	p	G120K	1	.	.	358	360	AAG	984	986	AAG	189;189;190	A,C;A,T,C;G	157,1;158,1,1;165	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	956	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	2078	137.2	1	SNP	p	N121D	0	.	.	361	363	AAC	987	989	AAC	190;193;192	A;A;C	161;164;165	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	956	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	2078	137.2	1	SNP	p	A121N	1	.	.	361	363	AAC	987	989	AAC	190;193;192	A;A;C	161;164;165	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3068	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5417	169.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	518	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1304	118.2	1	SNP	p	V57M	1	.	.	169	171	ATG	657	659	ATG	216;215;214	A,T;T;G	177,1;180;182	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
